Pfizer Buys Metsera, Gains Monthly GLP-1 Obesity Drug with 12.3% Weight Loss
PFE sits 21% above its 52-week low of $23.62.
Summary
Pfizer acquired Metsera, adding PF-3944, a monthly GLP-1 obesity drug that showed up to 12.3% weight loss in non-diabetic patients through week 28. The company set a 2028 target for its first regulatory approval in the weight-loss market, a concrete timeline for entering a rapidly growing segment. Separately, new Week 16 data for tilrekimig in atopic dermatitis showed vIGA 0/1 improvements of 30.3% vs 11.8% placebo in Stage 1 and 26-27% vs 0% in Stage 2, along with exploratory itch reduction of 42.5-50.8% vs 7.2% placebo. This follows the earlier Phase 2 primary endpoint report this morning and adds substantial detail on both the obesity pipeline and tilrekimig's secondary endpoints. The Metsera deal and 2028 approval target are new strategic disclosures that could shift positioning in the obesity market.
At the time of this announcement, PFE was trading at $28.59 on NYSE in the Life Sciences sector, with a market capitalization of approximately $162.6B. The 52-week trading range was $23.62 to $29.21. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.